gatifloxacin has been researched along with Mycoplasma dispar Infection in 2 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rao, SS | 1 |
| Raghunathan, R | 1 |
| Ekambaram, R | 1 |
| Raghunathan, M | 1 |
| Ishida, K | 1 |
| Kaku, M | 1 |
| Irifune, K | 1 |
| Mizukane, R | 1 |
| Takemura, H | 1 |
| Yoshida, R | 1 |
| Tanaka, H | 1 |
| Usui, T | 1 |
| Tomono, K | 1 |
| Suyama, N | 1 |
2 other studies available for gatifloxacin and Mycoplasma dispar Infection
| Article | Year |
|---|---|
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; | 2009 |
In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
Topics: Animals; Anti-Infective Agents; Cell Death; Cricetinae; Disease Models, Animal; Erythromycin; Fluoro | 1994 |